Cited by 64Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsIon Channels and Receptors

Modulation of the anti‐nociceptive effects of 2‐arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model

Open access
Desroches, J, Guindon, J, Lambert, C, Beaulieu, P·2008·British Journal of Pharmacology

Abstract

Background and purpose: There are limited options for the treatment of neuropathic pain. Endocannabinoids, such as anandamide and 2‐arachidonoyl glycerol (2‐AG), are promising pain modulators and there is recent evidence of interactions between anandamide and 2‐AG biosynthesis and metabolism. It has been clearly demonstrated that 2‐AG degradation is mainly catalysed not only by monoacylglycerol lipase (MGL) but also by a fatty acid amide hydrolase (FAAH). Inhibitors specifically targeting these two enzymes have also been described: URB602 and URB597, respectively. However, the anti‐nociceptive effects of the combination of peripherally injected 2‐AG, URB602 and URB597 in a neuropathic pain model have not yet been determined. This was performed in the presence or absence of cannabinoid CB 1 (AM251) and CB 2 (AM630) receptor antagonists. Experimental approach: Mechanical allodynia and thermal hyperalgesia were evaluated in 213 male Wistar rats allocated to 32 different groups. Drugs were injected subcutaneously in the dorsal surface of the hind paw (50 μL) 15 min before pain tests. Key results: 2‐AG, URB602 and URB597 significantly decreased mechanical allodynia and thermal hyperalgesia with ED50 of 1.6±1.5 and 127±83 μg for 2‐AG and URB602, respectively. These effects were mediated locally and were mostly inhibited by the two cannabinoid antagonists. Conclusions and implications: The combination of the three compounds did not produce any greater anti‐allodynic or anti‐hyperalgesic effects, suggesting that FAAH inhibition could reduce or limit the anti‐nociceptive effects of 2‐AG. Peripheral administration of endocannabinoids or MGL/FAAH inhibitors is a promising analgesic approach requiring further investigation. British Journal of Pharmacology (2008) 155 , 913–924; doi: 10.1038/bjp.2008.322 ; published online 11 August 2008

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjp.2008.322

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In both SNL and pSNL models, the FAAH inhibitor URB597 evoked anti-allodynic as well as anti-hyperalgesic effects.

    “In both SNL and pSNL models, the FAAH inhibitor URB597 evoked anti-allodynic (de Novellis et al, 2011), as well as anti-hyperalgesic effects (Desroches et al, 2008(Desroches et al, , 2014b)).”
  • 2-AG produces anti-hyperalgesic and anti-allodynic effects through activation of both peripheral CB1 and CB2 receptors.

    “whereas 2-AG produced anti-hyperalgesic and anti-allodynic effects through activation of both peripheral CB1 and CB2 receptors.67”
  • URB602 administered locally in the paw suppressed neuropathic nociception in the Seltzer model through activation of both CB1 and CB2 receptors.

    “The MGL inhibitor URB602 (which cannot be used systemically as a selective MGL inhibitor), administered locally in the paw, also suppressed neuropathic nociception in this model through activation of both CB1 and CB2 receptors.67”
  • URB597 administered locally in the paw, but not systemically, suppressed both thermal hyperalgesia and mechanical allodynia through a CB1 mechanism.

    “The FAAH inhibitor URB597, administered locally in the paw,67 but not systemically62 suppressed both thermal hyperalgesia and mechanical allodynia through a CB1 mechanism.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 60 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Desroches, J., Guindon, J., Lambert, C., & Beaulieu, P.
Affiliations
Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author
Beaulieu, P
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2008-11
Volume
155
Issue
6
Pages
913-924
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1999646805
Cited by
63
References
60
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2018: 4 · 2017: 6 · 2016: 2 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 6
FWCI
4.45
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
Keywords
2-arachidonoylglycerol, endocannabinoids, fatty acid amide hydrolase inhibition, monoacylglycerol lipase inhibition, URB597, neuropathic pain, mechanical allodynia, thermal hyperalgesia, CB1 receptor, CB2 receptor, antinociceptive effect, endocannabinoid metabolism
MeSH terms
Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Arachidonic Acids, Drug Combinations, Glycerides, Injections, Subcutaneous, Male, Models, Neurological, Monoacylglycerol Lipases, Pain, Pain Measurement, Rats, Wistar, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review